Hill J F, Bulpitt C J, Fletcher A E
J Hypertens Suppl. 1985 Nov;3(2):S91-4.
Two prospective multi-centre randomized trials were initiated to compare the relative efficacy and influence on quality of life of captopril, alone or in combination with hydrochlorothiazide, against either methyldopa, alone or in combination with hydrochlorothiazide, or oxprenolol in combination with chlorothalidone. The complaint rate, activity index and psychiatric morbidity were evaluated as indices of quality of life. Captopril was associated with a significantly (P less than 0.05) greater reduction in complaint rate compared with methyldopa and a tendency for less symptoms of depression compared with oxprenolol (P = 0.06), the latter drug being associated with an increase in depression scores. The trends in quality of life indices in the captopril-treated patients would suggest the need for double-blind placebo-controlled trials to investigate these apparent benefits.
开展了两项前瞻性多中心随机试验，以比较卡托普利单独使用或与氢氯噻嗪联合使用，与甲基多巴单独使用或与氢氯噻嗪联合使用，或氧烯洛尔与氯噻酮联合使用时的相对疗效及对生活质量的影响。将主诉率、活动指数和精神疾病发病率作为生活质量指标进行评估。与甲基多巴相比，卡托普利使主诉率显著降低（P<0.05），与氧烯洛尔相比，卡托普利有使抑郁症状减少的趋势（P = 0.06），后一种药物与抑郁评分增加有关。卡托普利治疗患者的生活质量指标趋势表明，需要进行双盲安慰剂对照试验来研究这些明显的益处。
